The Clinical Research Of Tripterygium Glycosides In Treating Ankylosing Spondylitis

Objective:Evaluating Tripterygium Glycosides's clinical effect of treating ankylosing spondylitis (AS) by surveying the change of Bath Ankylosing Spondylitis Patient Global Score (BAS-G), Bath Ankylosing Spondylitis Disease Activity Score Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), spinal pain VAS,at least 20% improvement in the Assessment in AS (ASAS20), ASAS40 and erythrocyte sedimentation rate (ESR),cross-reacting protein (CRP).Evaluating Tripterygium Glycosides's security of treating ankylosing spondylitis by surveying the influence on blood routine and liver function of patients.Methods:65 patients were randomly divided into an experimental group (45 cases) and a control group (20 cases).Treatments lasted 6 weeks, and observation points were week 0,week 3,week 6. The experimental group was administered with 2 doses of Tripterygium Glycosides (TWG),3 times per day;the control group was administered with salicylazosulfapyridine 250 mg tid,1 week to 500mg tid,2 weeks to 1000mg bid, up to the end. Both groups can take 75mg Diclofenac retard tablet when suffering unbearable pain in a day, not more than two tablets, making relevant records and monitoring adverse reactions recorded accordingly.Results:In the aspect of ASAS20 and ASAS40, at week 3, the percent of patients in the experimental group showing ASAS20 and ASAS40 response were 73.3% and 40% respectively, which were significantly more than 30% and 10% in the control group respectively, and there was statistically significance (P<0.01 and P<0.05 respectively). At week 6, the percent of patients in the experimental group showing ASAS20 and ASAS40 response were 88.9% and 77.8% respectively, which were more than 60% and 35% in the control group respectively, and there was statistically significance (P<0.01 and P<0.01 respectively).In the aspect of BAS-G, BASDAI, BASMI, BASFI and spinal pain VAS, at week 3,The experimental group were improved in BAS-G, BASDAI, BASMI, BASFI arid spinal pain VAS, and there was statistically significance (P<0.05);the control group were improved in BAS-G, BASDAI, BASFI and spinal pain VAS, and there was significant difference between them(P<0.05).Although there was improvement in BASMI, it was not statistically significant(P>0.05).At week 6, two groups were improved in BAS-G, BASDAI, BASMI, BASFI and spinal pain VAS, and there was statistically significance (P<0.05).The experimental group was better than control group in BAS-G, BASDAI, BASMI, BASFI and spinal pain VAS, and there was statistically significance (P<0.05)Conclusion:According to the results of 6-week randomized controlled study, the therapeutic effect of TWG of treatment on ankylosing spondylitis is superior to salicylazosulfapyridine, and the application in the short term is comparatively safety.